Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile

Date: October 18, 2016
Pages: 68
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C7C0B528DF9EN
Leaflet:

Download PDF Leaflet

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile
Summary

Cerus Corporation (Cerus) is a biomedical products manufacturing company which develops and commercializes Intercept Blood System for blood safety. The company has rights of Intercept for three blood components, namely, platelets, red blood cells and plasma. The system is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells (WBC) included in donated blood components intended for transfusion. It markets its product in the US, Europe, Russia, the Middle East and selected countries of other regions of the world for the treatment of both platelets and plasma for transfusions and it is also being developed for the treatment of red blood cells. Cerus is headquartered in Concord, California, the US.

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016
Cerus Corporation, Medical Equipment Deals By Type, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals By Market, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deal Details
Partnerships
Cerus Terminates Licensing Agreement With BioOne
Cerus Enters into Agreement with Haemonetics
Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan
Cerus Enters into Co-Marketing Agreement with Biomedica Foscama
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma
Cerus Enters Into Distribution Agreement With Ilex Biotech
Cerus Enters Into Agreement With CSL
Equity Offering
Cerus Plans to Raise USD70 Million in Public Offering of Shares
Cerus Prices Public Offering of Shares for USD70 Million
Cerus Completes Public Offering Of Shares For US$40.3 Million
Cerus Completes Underwritten Public Offering Of US$21 Million
Cerus Corporation - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Financial Announcements
Aug 04, 2016: Cerus Reports Second Quarter 2016 Results
May 03, 2016: Cerus Corporation Reports First Quarter 2016 Results
Mar 08, 2016: Cerus Reports Fourth Quarter and Year End 2015 Results
Nov 05, 2015: Cerus Reports Third Quarter 2015 Results
Aug 06, 2015: Cerus Reports Second Quarter 2015 Results
May 05, 2015: Cerus Reports First Quarter 2015 Results
Feb 26, 2015: Cerus Reports Fourth Quarter and Year-End 2014 Results
Corporate Communications
Aug 09, 2016: Vivek Jayaraman Appointed as Cerus Corporation’s Chief Commercial Officer
Jan 11, 2016: Cerus Appoints New Leadership for Europe, Middle East and Africa Region
Jun 08, 2015: Richard J. Benjamin, MD PhD Appointed as Cerus Corporation’s New Chief Medical Officer
Product News
Mar 16, 2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma
Mar 15, 2016: Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA’s Revised Guidance Document on Bacterial Safety Standards for Platelets
Mar 09, 2016: Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology
Feb 09, 2016: Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma
Jan 14, 2016: AABB Authorizes Use of the INTERCEPT Blood System for Platelets to Reduce the Risk of Transfusion-Associated Graft Versus Host Disease
Jan 05, 2016: Cerus Announces Agreement with Blood Systems for the Use of INTERCEPT Platelets and Plasma
Dec 10, 2015: Cerus Announces Agreement with the National Transfusiology Center of Mongolia for the Use of INTERCEPT Platelets and Plasma
Dec 07, 2015: Cerus and Shepeard Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
Nov 02, 2015: Cerus Announces CMS Issuance of Permanent P-Codes for Outpatient Hospital Billing of Pathogen-Reduced Platelets and Plasma
Apr 27, 2015: Cerus To Present At AABB Symposium On Pathogen-Reduced Components
Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets
Feb 27, 2015: Cerus Signs INTERCEPT Platelet Agreement With Sweden’s Largest Blood Product Supplier
Jan 28, 2015: Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System
Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
Product Approvals
Mar 16, 2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma
Clinical Trials
Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets
Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
Other Significant Developments
Oct 10, 2016: Cerus Announces that Hemolife Fundacion Banco Nacional de Sangre Has Entered into Routine Use of the INTERCEPT Blood System
Jul 11, 2016: Cerus Provides an Update on Adoption by Blood Centers of America Members for the INTERCEPT Blood System for Platelets and Plasma
Oct 21, 2015: Cerus Announces New Agreement With Fresenius Kabi for the Production of INTERCEPT Blood System Kits
Jul 13, 2015: Cerus and Bonfils Blood Center Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer 68

LIST OF TABLES

Cerus Corporation, Medical Equipment, Key Facts, 2015
Cerus Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016
Cerus Corporation, Medical Equipment Deals By Type, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016
Cerus Corporation, Deals By Market, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016
Cerus Terminates Licensing Agreement With BioOne
Cerus Enters into Agreement with Haemonetics
Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan
Cerus Enters into Co-Marketing Agreement with Biomedica Foscama
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma
Cerus Enters Into Distribution Agreement With Ilex Biotech
Cerus Enters Into Agreement With CSL
Cerus Plans to Raise USD70 Million in Public Offering of Shares
Cerus Prices Public Offering of Shares for USD70 Million
Cerus Completes Public Offering Of Shares For US$40.3 Million
Cerus Completes Underwritten Public Offering Of US$21 Million
Cerus Corporation, Key Competitors
Cerus Corporation, Key Employees
Cerus Corporation, Subsidiaries 28

LIST OF FIGURES

Cerus Corporation, Medical Equipment, Deals by Type, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals By Market, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals by Type, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016
Cerus Corporation, Medical Equipment, Deals by Market, 2010 to YTD 2016
Skip to top


Ask Your Question

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: